These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23529786)

  • 21. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis.
    Sastre J; Mullol J; Valero A; Valiente R;
    Curr Med Res Opin; 2012 Jan; 28(1):121-30. PubMed ID: 22077106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive Performance Effects of Bilastine 20 mg During 6 Hours at 8000 ft Cabin Altitude.
    Valk PJ; Simons R; Jetten AM; Valiente R; Labeaga L
    Aerosp Med Hum Perform; 2016 Jul; 87(7):622-7. PubMed ID: 27503042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans.
    Church MK
    Inflamm Res; 2011 Dec; 60(12):1107-12. PubMed ID: 21874559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
    Novák Z; Yáñez A; Kiss I; Kuna P; Tortajada-Girbés M; Valiente R;
    Pediatr Allergy Immunol; 2016 Aug; 27(5):493-8. PubMed ID: 26918853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Abdelshafy AM; Abdallah SY; Hassan AF; Mohamed HA; Kamal NM; Ali ST; Abdelhaleem IA
    Am J Rhinol Allergy; 2022 Sep; 36(5):684-694. PubMed ID: 35593100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial.
    Okubo K; Gotoh M; Togawa M; Saito A; Ohashi Y
    Auris Nasus Larynx; 2017 Jun; 44(3):294-301. PubMed ID: 27561709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of the effect of bilastine and cetirizine on cognitive functions at ground level and at an altitude of 4,000 m simulated in hypobaric chamber: a randomized, double-blind, placebo-controlled, cross-over study.
    Reményi Á; Grósz A; Szabó SA; Tótka Z; Molnár D; Helfferich F
    Expert Opin Drug Saf; 2018 Sep; 17(9):859-868. PubMed ID: 30032673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How bilastine is used to treat allergic rhinitis and urticaria in children.
    Rodríguez Del Río P; Rodríguez Fernández F; Ballester Asensio E; Tortajada-Girbés M
    Immunotherapy; 2022 Jan; 14(1):77-89. PubMed ID: 34850647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
    Bachert C; Kuna P; Sanquer F; Ivan P; Dimitrov V; Gorina MM; van de Heyning P; Loureiro A;
    Allergy; 2009 Jan; 64(1):158-65. PubMed ID: 19132976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bilastine: in allergic rhinitis and urticaria.
    Carter NJ
    Drugs; 2012 Jun; 72(9):1257-69. PubMed ID: 22686617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria.
    Krause K; Spohr A; Zuberbier T; Church MK; Maurer M
    Allergy; 2013 Jul; 68(7):921-8. PubMed ID: 23742030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Okubo K; Gotoh M; Asako M; Nomura Y; Togawa M; Saito A; Honda T; Ohashi Y
    Allergol Int; 2017 Jan; 66(1):97-105. PubMed ID: 27421817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilastine: an environmental risk assessment.
    Lucero ML; Peither A; Ledo F
    Drug Chem Toxicol; 2015 Oct; 38(4):460-8. PubMed ID: 25609003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
    Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
    Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integration of preclinical and clinical knowledge to predict intravenous PK in human: bilastine case study.
    Vozmediano V; Ortega I; Lukas JC; Gonzalo A; Rodriguez M; Lucero ML
    Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):33-41. PubMed ID: 23619917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments.
    García-Gea C; Martínez-Colomer J; Antonijoan RM; Valiente R; Barbanoj MJ
    J Clin Psychopharmacol; 2008 Dec; 28(6):675-85. PubMed ID: 19011437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bilastine as a potential treatment in allergic rhinitis.
    Kowal K; DuBuske L
    Am J Rhinol Allergy; 2014; 28(4):312-6. PubMed ID: 25197918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
    Zuberbier T; Oanta A; Bogacka E; Medina I; Wesel F; Uhl P; Antépara I; Jáuregui I; Valiente R;
    Allergy; 2010 Apr; 65(4):516-28. PubMed ID: 19860762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.